Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

433 results about "Encephalopathy" patented technology

A medical term used to describe a disease that affects brain structure or function.

Bifidobacterium animalis subsp. lactis and use thereof

ActiveUS20240417674A1Milk preparationNervous disorderBiotechnologyPsychiatric disturbances
Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

TIPS postoperative hepatic encephalopathy prediction system based on multi-modal feature fusion

The invention discloses a TIPS postoperative hepatic encephalopathy prediction system based on multi-modal feature fusion. The TIPS postoperative hepatic encephalopathy prediction system comprises a data preprocessing module, a feature extraction module based on pre-training parameters, a feature fusion module based on a cross attention mechanism and a system network module of a classifier module. The feature extraction module comprises a full connection operation unit and a convolution operation unit; the fusion module comprises a pooling unit and a cross attention unit. According to the model, images and clinical data of a patient are utilized, internal information of two kinds of modal data is extracted through two paths of feature extraction networks, finally, extracted useful information is fused through a multi-head attention mechanism, and information obtained through fusion is input into a classifier to obtain a prediction result. The model realizes supervised classification. Meanwhile, in the CT image feature extraction stage of the network, the pre-training parameters of the classic network are utilized, so that the network model is easier to train.
Owner:FIRST HOSPITAL OF SHANXI MEDICAL UNIV

Quality control of BAG3 and proteins in brain

The BAG3 proteins are useful in the treatment of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Lewy body disease, vascular dementia, mixed dementia and traumatic brain injury, such as chronic traumatic encephalopathy (CTE). A therapeutic BAG3 composition, use of BAG3, and a method of treatment of BAG3 are described.
Owner:TEMPLE UNIV

Construction method and system based on encephalopathy nursing knowledge base

The invention relates to the technical field of database construction, in particular to a construction method and system based on an encephalopathy nursing knowledge base. The method comprises the following steps: acquiring multi-source encephalopathy data; performing structured data screening on the multi-source encephalopathy data to generate structured encephalopathy data and unstructured encephalopathy data; performing multi-modal data structured layering on the unstructured encephalopathy data to generate multi-modal structured layered data; performing data preprocessing on the multi-modal structured hierarchical data and the structured encephalopathy data to generate a standard structured encephalopathy data set; performing context analysis on the standard structured encephalopathy data set to generate an encephalopathy information semantic vector set; and performing redundant relation pruning processing on the encephalopathy information semantic vector set to generate spatial semantic optimization data. According to the method, by integrating multi-source data, structured and unstructured information, real-time dynamic mapping nursing requirements and system feedback evaluation, the construction quality and practicability of the encephalopathy nursing knowledge base are improved.
Owner:XIAN TRADITIONAL CHINESE MEDICINE ENCEPHALOPATHY HOSPITAL CO LTD

Biomarker for sepsis encephalopathy and application thereof

The invention provides a biomarker for sepsis encephalopathy and application of the biomarker. The biomarker is selected from any one or a combination of more than two of 5-HTP, 5-HIAA or 5-HIAA / 5-HT according to a ratio of 5-HTP to 5-HIAA to 5-HT. The biomarker has the advantages of high sensitivity and high precision, and development and utilization of the key biomarker have important value in precise diagnosis, prognosis, subsequent treatment and drug screening of sepsis encephalopathy.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Humanized Anti-TDP-43 Binding Molecules and Uses Thereof

The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and / or treat a disease, disorder and / or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Owner:AC IMMUNE SA

Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.
Owner:DEUT ZENT FUER NEURODEGENERATIVE ERKRANKUNGEN EV +1

Intelligent feedback type encephalopathy rehabilitation guidance training system

The invention discloses an intelligent feedback type encephalopathy rehabilitation guidance training system which collects physiological data of a patient in real time through a wearable device or a brain-computer interface, carries out accurate evaluation and generates a personalized training plan in combination with individual differences and rehabilitation progress of the patient. In the training process, the system provides immediate feedback and guidance, and correctness and effectiveness of training are ensured. Meanwhile, the system also integrates comprehensive rehabilitation guidance functions, including cognition, language and motion function recovery, psychological support, life skill training and the like; through the cloud data processing center, medical personnel can remotely monitor the rehabilitation condition of a patient and adjust a training plan in time. The system not only improves the pertinence and effectiveness of rehabilitation training, but also enhances the rehabilitation confidence and participation degree of the patient. In a word, the intelligent feedback type encephalopathy rehabilitation guidance training system provides all-around and personalized rehabilitation services for encephalopathy patients, and the rehabilitation effect and the satisfaction degree of the patients are remarkably improved.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAN MEDICAL UNIV

Bifidobacterium animalis subsp. lactis and use thereof

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

Use of cryab in medical diagnosis and therapy

The invention discloses application of an alpha B crystal protein (CRYAB) as a marker in diagnosis or prediction of narcolepsy encephalopathy, especially epilepsy. The invention also discloses application of the alpha B crystal protein in preparation of drugs or kits for preventing or treating narcolepsy encephalopathy, especially epilepsy.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Gene therapy for stxbp1 encephalopathy

PCT designated stageWO2025213064A1Nervous disorderPeptide/protein ingredientsSTXBP1Medicine
Aspects of the invention provide an AAV product that delivers an STXBP1 gene supplementation or replacement strategy throughout the human CNS at levels of DNA biodistribution, RNA expression, and hSTXBPlb protein levels expected to restore function in STXBP1 encephalopathy patients.
Owner:CAPSIDA BIOTHERAPEUTICS INC +1

Methods of treating or controlling cytotoxic cerebral edema

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
Owner:AEROMICS INC

Gene therapy for stxbp1 encephalopathy

PCT designated stageWO2025213056A1Nervous disorderPeptide/protein ingredientsSTXBP1Haploinsufficiency
The disclosure concerns compositions and methods for treatment of encephalopathies, including encephalopathies caused by, or associated with, and STXBP1 haploinsufficiency or mutation. Compositions and methods provided herein encompass AAV particles that encapsidate the STXBP1 transgene and allow for STXBP1 expression, including expression of STXBP1 in central and / or peripheral nervous system cells.
Owner:CAPSIDA BIOTHERAPEUTICS INC +1

Compounds and methods for modulating SCN2a

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in a cell or subject, and in certain instances reducing the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, a Developmental and Epileptic Encephalopathy, an intellectual disability, or an autism spectrum disorder. Such symptoms and hallmarks include, but are not limited to seizures, hypotonia, sensory integration disorders, motor development delays and dysfunctions, intellectual and cognitive dysfunctions, movement and balance dysfunctions, visual dysfunctions, delayed language and speech, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.
Owner:IONIS PHARMACEUTICALS INC

Transcranial magnetic stimulation therapeutic apparatus

ActiveCN222357891UAvoid affecting the effect of electromagnetic treatmentImprove comfortElectrotherapyMagnetotherapyMechanical engineeringMagnetic brain stimulation
The utility model belongs to the field of transcranial magnetic therapeutic instruments, and particularly relates to a transcranial magnetic stimulation therapeutic instrument which comprises an instrument body, a head limiting structure is installed in the middle of the front side of the instrument body, a movable plate is integrally arranged at the bottom of the head limiting structure, and a connecting plate is bonded to the inner wall of the movable plate through glue. A limiting block is fixed to the bottom of the movable plate, a head cushion is arranged on the inner wall of the limiting block, an electromagnetic treatment block is arranged in the middle of the interior of the instrument body, electromagnetic connecting wires are connected to the periphery of the electromagnetic treatment block, and electromagnetic treatment sub-blocks are arranged at the bottom ends of the electromagnetic connecting wires; the head limiting structure can play a role in limiting the wearing position of the instrument main body, avoids the situation that some encephalopathy patients of which the limbs cannot be controlled automatically act too much during transcranial magnetic stimulation treatment to affect the electromagnetic treatment effect, can improve the comfort level, does not affect the wearing experience, and is light in structure, convenient to wear, simple in structure and convenient to carry.
Owner:AIR FORCE HOSPITAL OF THE EASTERN THEATER COMMAND OF THE CHINESE PEOPLES LIBERATION ARMY

Oligosaccharide compositions and methods of use thereof for reducing ammonia levels

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).
Owner:DSM NUTRITIONAL PRODUCTS LLC

Compositions comprising isolated endothelial progenitor cells and uses thereof

The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+ / - PDGFRA+ / - EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.
Owner:THE UNIVERSITY OF QUEENSLAND

Method for constructing mouse nerve injury animal model based on poxvirus infection

PendingCN119032898AObvious edemaObvious necrosisAnimal husbandryDiseaseAccessory Olfactory Bulb
The invention relates to the technical field of biomedicine, and discloses a method for constructing a mouse nerve injury animal model based on poxvirus infection, the model is constructed by infecting a mouse nasal drop with poxvirus, and the model can simulate nerve injury and related pathological changes caused by the poxvirus. The vaccinia virus used in the invention can cause serious infection of mice, cause certain damage to blood-brain barriers at olfactory bulb parts, and cause activation and increase of glial nerve cells of olfactory bulb parts and reduction of olfactory nerve quantity or vitality. In view of high conservative property of the poxvirus, the model has remarkable application value in research in the fields of prevention and treatment of related diseases and related pharmacy. For example, the method can be used for research and development and effectiveness screening and evaluation of candidate therapeutic or prophylactic drugs and vaccines for poxvirus infectious olfactory nerve injury. The model is helpful for accelerating the discovery and optimization of a new therapy and improving the prevention capability of coping with poxvirus infection related nerve injury diseases (encephalopathy) in the future.
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT

Application of lanthanum carbonate in preparation of medicine for treating hepatic encephalopathy

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. According to the application of lanthanum carbonate in preparation of the medicine for treating hepatic encephalopathy, the medicine comprises lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate, the medicine is ground and then mixed with food to prepare a medicine mixture, and the medicine mixture is prepared into the medicine for treating hepatic encephalopathy. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%. According to the application, the blood ammonia is reduced based on the glutaminase, the hepatic encephalopathy is reversed by reducing the blood ammonia and systemic inflammation, and the liver function is recovered by regulating the inflammation, so that the hepatic encephalopathy is favorably cured, a good treatment effect is shown, and a new candidate medicine is provided for clinically treating the hepatic encephalopathy.
Owner:南昌大学第一附属医院

Brain electrical emotion recognition method and system based on multi-branch feature fusion

The invention belongs to the field of cross-subject electroencephalogram emotion recognition, and discloses an electroencephalogram emotion recognition method and system based on multi-branch feature fusion, and the method comprises the steps: 1, obtaining electroencephalogram data; 2, preprocessing the data; 3, five-frequency-band features are extracted; 4, obtaining a target domain and a source domain; 5, dividing a data set; step 6, inputting a feature fusion network; step 7, obtaining time domain-frequency domain features and spatial features; 8, obtaining an advanced time domain-frequency domain feature; step 9, obtaining an output; 10, obtaining adapter fine tuning data output; 11, obtaining a prediction emotion probability; 12, calculating a cross entropy loss function; step 13, obtaining a model trained by the current testee; and step 14, obtaining a trained model of all testees. According to the method, transfer learning among different samples is more accurately achieved, and the overall effect of cross-subject electroencephalogram emotion recognition is effectively improved.
Owner:NORTHWEST UNIV

Anti-TDP-43 binding molecules and uses thereof

The invention relates to anti-TDP-43 binding molecules and uses thereof. The present invention is in the field of trans-activation responsive DNA binding proteins (TARDB or also referred to as TDP-43) having a molecular weight of 43 kDa. The present invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen binding fragments or derivatives thereof, and uses thereof. The present invention provides means and methods for diagnosing, preventing, ameliorating and / or treating diseases, disorders and / or abnormalities associated with TDP-43 aggregates, including, but not limited to, frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE), and edge-dominant age-related TDP-43 encephalopathy (LATE).
Owner:AC IMMUNE SA

Method for processing an electroencephalogram signal

The invention pertains to a new computer-implemented method for processing an EEG signal, that makes it possible to extract information about cerebral damage in full-term babies, born in asphyxia context, for help in an indication for treatment of hypoxic-ischemic encephalopathy (HIE), by computing a power spectral density (PSD) of an EEG signal, transforming the PSD by a mathematical function, processing the transformed values by data binning, and creating a probability distribution of the durations of the binned values.
Owner:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (APHP) +4

Pharmaceutical composition for treating KCNQ2 developmental epileptic encephalopathy, nucleic acid construct and application

The invention discloses a pharmaceutical composition for treating KCNQ2 developmental epileptic encephalopathy, a nucleic acid construct and application of the pharmaceutical composition and the nucleic acid construct. According to the invention, by introducing a nucleic acid construct carrying the hKCNQ2 gene into a KCNQ2A294V / + developmental epileptic encephalopathy animal model and a human forebrain neuron model, the effectiveness of the nucleic acid construct in improving the expression level of the KCNQ2 and improving related neuropathological mechanisms is verified. Not only is a new hope provided for treatment of KCNQ2-related developmental epileptic encephalopathy provided, but also a new direction is opened up for application of gene therapy in neurodevelopmental diseases.
Owner:SHENZHEN RUIAN KANGCHENG BIOTECHNOLOGY CO LTD

Methods for treating hepatic encephalopathy

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA +3

Heterocyclic compounds as modulators of CAV2.3

PCT designated stageWO2025158150A1Nervous disorderOrganic chemistryCalcium fluxNervous system
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1, R2, R3, R12, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Phelan-McDermid and Fragile X syndromes.
Owner:LARIO THERAPEUTICS LTD

Sulfonamide compounds for the treatment of neurological conditions

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.
Owner:LARIO THERAPEUTICS LTD

Polyethylene glycol modified magnesium boride nanosheet and application thereof in treatment of acute liver failure and concurrent hepatic encephalopathy caused by acetaminophen

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.
Owner:HEFEI UNIV OF TECH

Auxiliary gloves for rehabilitation training of encephalopathy

The utility model is suitable for the technical field of rehabilitation training gloves, and provides an auxiliary glove for rehabilitation training of encephalopathy. The male magic tape is sewn on the outer wall of one side of the wrist strap through a needle and a thread; the female magic tape is sewn on the outer wall of the other side of the wrist strap through a needle and a thread; the corrugated telescopic band is fixed at the top of the wrist band; the connecting belt is fixed at the top of the corrugated telescopic belt; the palm sleeve is fixed at the top of the connecting band; the fingerstalls and the palm center belt are integrally formed on the inner side wall of the palm sleeve, and the fingerstalls are located above the palm center belt; expansion and contraction of the first air bag and the second air bag are achieved by controlling inlet and outlet of air in the first air bag and the second air bag, angle adjustment of the wrist strap and the palm sleeve is achieved through pushing force and pulling force generated by deformation of the first air bag and the second air bag, and therefore wrist movement is controlled, and rehabilitation training of hand wrist joints is facilitated. Manual auxiliary training is not needed, and manpower is greatly saved.
Owner:王夏